Susanne Sheehy, BM BCh, MRCP, DTM&H and Joel Meyer, BM BCh, MRCP
The decline in numbers of healthy volunteers who participate in clinical trials has the potential to become a key rate-limiting factor in vaccine development.
Laura N. Gitlin, PhD and Nancy A. Hodgson, PhD, RN
As a matter of medical ethics, physicians must address the health care needs of and be advocates for family caregivers of their patients with dementia.
AMA J Ethics. 2016; 18(12):1171-1181. doi:
10.1001/journalofethics.2016.18.12.ecas1-1612.
Timothy Cavanaugh, MD, Ruben Hopwood, MDiv, PhD, and Cei Lambert, MFA
The informed consent model for gender-affirming medical treatment emphasizes patient autonomy in choosing care without involving mental health professionals.
AMA J Ethics. 2016; 18(11):1147-1155. doi:
10.1001/journalofethics.2016.18.11.sect1-1611.
B. Rashmi Borah, Nicolle K. Strand, JD, MBioethics, and Kata L. Chillag, PhD
The Bioethics Commission’s recommendations to include research participants with impaired consent capacity provide an ethical foundation for neuroscience.
AMA J Ethics. 2016; 18(12):1192-1198. doi:
10.1001/journalofethics.2016.18.12.nlit1-1612.
This month, AMA Journal of Ethics' theme editor Cameron Waldman, a second-year medical student at Albany Medical College, interviewed Aron Janssen, MD, about how healthcare professionals can better serve their transgender patients.
The American College of Physicians and the Federation of State Medical Boards’ guidelines for online medical professionalism apply existing norms of communication and confidentiality to new settings but will need to be modified in light of technological advances and unanswered questions.
AMA J Ethics. 2015; 17(5):441-447. doi:
10.1001/journalofethics.2015.17.5.nlit1-1505.
Daphne C. Ferrer, MD and Peter M. Yellowlees, MBBS, MD
Telepsychiatry extends access to psychiatric treatment to those who might not otherwise get it, but licensure problems and the risk of boundary violations between patients and physicians need to be worked out.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.